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Abstract
Background: Patients with chronic kidney disease (CKD) have a high symptoms burden that is related to a poor
health-related quality of life (HRQoL) and high costs of care. Validated instruments may be useful for assessing the
symptoms and monitoring outcomes in these patients. The Palliative care Outcome Scale-Symptoms Renal (POS-S
Renal) is a patient-reported outcome measure for assessing symptoms in CKD stage 4–5. This study is the first
cross-cultural adaptation and psychometric analysis of this clinical tool. The purpose of this study is to carry out a
cross-cultural adaptation of the POS-S Renal for Spanish-speaking patients, and to perform an analysis of the
psychometric properties of this questionnaire.
Methods: The English version of the POS-S Renal was culturally adapted and translated into Spanish using a double
forward and backward method. An expert panel evaluated the content validity. The questionnaire was pilot-tested in
30 patients. A total of 200 patients with CKD stage 4–5 filled in a modified Spanish version of the POS-S Renal and the
MSAS-SF. Statistical analysis to evaluate the psychometric properties of the questionnaire was carried out.
Results: The content validity index (CVI) was 0.97, which indicated that the content of the instrument is an adequate
reflection of the symptoms in advanced CKD (ACKD). The factor analysis indicated a two-factor solution explaining 35.
05% of total variance. The confirmatory factor analysis (CFA) demonstrated that the two factor model was well
supported (comparative fit index = 0.98, root mean square error of approximation = 0.068). This assessment tool
demonstrated a satisfactory test–retest reliability (r = 0.909 to factor 1, r = 0.695 to factor 2, r = 0.887 to total score),
good internal consistency to factor 1 (α = 0.78) and moderate internal consistency to factor 2 (α = 0.56). Concurrent
criterion-related validity with MSAS-SF was also demonstrated, with r = 0.860, which indicated a high degree of
correlation with a validated instrument that has been used in patients with ACKD.
Conclusions: The Spanish modified version of the POS-S Renal is a reliable and valid instrument that can be used to
assess symptoms in Spanish patients with CKD stage 4–5.
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Background
A patient with Advanced Chronic Kidney Disease
(ACKD)(defined, according to the international guide-
lines, as chronic kidney disease at stage 4 or 5 with a
glomerular filtration rate < 30 ml/min) has an increased
burden of physical and psychological symptoms that are
associated with a poor health-related quality of life
(HRQoL) [1–3]. Symptoms such as tiredness, pruritus,
constipation, pain, sleep alterations, anxiety, dyspnoea,
nausea, restless legs and depression have a high prevalence
in these patients [4, 5]. As uncontrolled symptoms at the
end of life lead to greater suffering, their treatment in the
advanced phases of the disease is a priority [6].
Patient reported outcome (PRO) instruments are gen-
erally used to assess patients’ functional status, quality of
life and symptoms [7]. This is especially important in
patients with chronic diseases such as chronic kidney
disease (CKD), in which PRO measures can be used to
evaluate, monitor, and facilitate the introduction of
interventions [8].
The use of validated scales may therefore be useful for
standardising the evaluation of symptoms and monitoring
the healthcare outcomes of these patients [9]. Because of
the variety of symptoms that might be suffered by a kidney
patient, tools that can evaluate a wide range of symptoms
are recommended. In addition, it is useful to have instru-
ments that can be administered pre- and post-dialysis
start, in order to better monitor patients as they progress
through CKD stages. Among the tools most used for the
study of symptoms in kidney patients are questionnaires
that are not specific to renal patients, such as the Memor-
ial Symptom Assessment Scale-Short Form(MSAS-SF)
[10], questionnaires modified for use with patients on dia-
lysis, such as the Edmonton Symptom Assessment System
(ESAS) [11], and other specific questionnaires that have
been developed to measure symptoms in ACKD, such as
the Dialysis Symptom Index (DSI) [12] and the Palliative
care Outcome Scale-Symptoms Renal (POS-S Renal) [13].
There are no specific symptom assessment questionnaires
for CKD patients that have been adapted to the Spanish
culture, Spanish being one of the most commonly spoken
languages in the world and that enable us to evaluate the
intensity of the various symptoms in this population [14].
The POS-S Renal is a questionnaire that has been de-
signed to evaluate symptoms in ACKD, and it has demon-
strated its usefulness in clinical practice and in research
[13, 15]. Thus it is a tool recommended for the evaluation
of symptoms in this population [9, 16, 17]. There are at
present no studies that have assessed the psychometric
properties of this questionnaire.
The aims of this study were to carry out a cross-
cultural adaptation of the POS-S Renal into Spanish and
to perform an analysis of test-retest reliability, internal
consistency, internal structure, and concurrent criterion-
related validity with the MSAS-SF, a previously validated
PRO measure which has been used in patients with
ACKD [18–20].
Methods
This study was conducted in two principal phases: trans-
lation and cross-cultural adaptation, and then validation.
Phase 1: Translation and cross-cultural adaptation
Translation
Translation of the original English version of the POS-S
Renal was performed using a double forward and backward
method following recommended guidelines [21]. This
method includes: 1) two forward translations from the
source language into the target language; 2) reconciliation
of the two versions; 3) two backward translations from the
target language version to the source language; and 4)
reconciliation of the two versions and comparison with the
original to create a consensus document.
There were two independent translations into Spanish.
The two versions were compared and, after discussion,
merged into a single document: the preliminary Spanish
version of POS-S Renal. Two native English translators
performed a backward translation of this version to the
source language to make, after discussion, a single docu-
ment. This document was compared with the original to
check the conceptual and semantic equivalence between
the two texts (Fig. 1).
Content validity
Content validity occurred during this phase to evaluate
the degree to which the content of the instrument is an
adequate reflection of the construct to be measured. An
expert panel review was conducted to assess content
validity. A total of 14 healthcare professionals (experts
in palliative care and nephrology), researchers, patients
with ACKD and carers of ACKD patients were invited to
join the expert panel, but only eight of them (six health-
care professionals, one patient and one carer) agreed to
participate. The other six declined because of lack of time
(n = 4) or lack of knowledge about the subject (n = 2).
Content validity was determined using the COSMIN
checklist [22]. Individually, the expert participants were
asked to rate their level of agreement with the relevance
of each item. One symptom (cramps) was added after
discussion. The response choices for this item were set
to be identical to the response choices for the other
17items. This symptom was prevalent (29%), but had
not previously been included in this symptom assess-
ment tool. Content validity was determined using the
Lawshe content validity index (CVI);employing the
formula suggested by Lawshe, the CVI was 0.97, with
items ranging from 0.75 to 1.00, which is acceptable,
according to Lawshe and Davis [23, 24].
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Pilot study
A pilot study was conducted with 30 patients to identify
problematic items and to ensure that the adapted ques-
tionnaire was understandable and acceptable to the
patients.
Phase 2: Validation study
Sample, setting and data collection
Two hundred (200) patients (aged 66.45 ± 14.52, 65%
male) participated in the present study. Their socio-
demographic and clinical characteristics are shown
in Table 1. All participants were recruited at the
Nephrology Service at Carlos Haya University Hospital in
Málaga (Spain), and, after receiving information about the
project, signed to give their informed consent. The
inclusion criteria were: adult Spanish-speaking patients
with ACKD receiving dialysis or renal conservative
management (without dialysis).
By contrast, there were three exclusion criteria: the
patient’s refusal to participate in the study, mild cogni-
tive impairment and the patient being under the age of
18 years. The data were collected between April 2015
and September 2015.
Data were collected during face-to-face interviews.
When possible, the questionnaires (POS-S Renal and
MSAS-SF) were self-completed. Otherwise, the inter-
viewer read out and filled in the instruments according to
the patient’s responses. In the case of patients managed
conservatively (without dialysis), the interviews were con-
ducted in the routine medical consultation room, whereas
patients in dialysis were interviewed in the dialysis room.
The interviewers first recorded the patient’s clinical socio-
demographic data, and afterwards asked the patients to
complete the POS-S Renal and the MSAS-SF.
Questionnaires
POS-S renal
This is a patient-completed questionnaire that has been
developed to assess symptoms in ACKD. The question-
naire identifies the presence and severity of 17 symp-
toms during the week prior to the completion of the
questionnaire [13]. If the symptom is present, the inten-
sity of each symptom is rated on a 5-point Likert scale
(0 to 4) ranging from ‘none’ to ‘overwhelming’.
In addition, the questionnaire provides open fields to
list the main problems experienced. This open-ended
question gives the patient the opportunity to emphasise
the importance of a symptom, or to indicate other
symptoms not included in the questionnaire. In addition,
a symptom severity score can be calculated from the
questionnaire as a whole. If one apportions a number to
the range of severity of each symptom (from 0 to 4), the
maximum global symptom severity score is 68. This
simple tool is used widely and is recommended as the
tool of choice for ACKD [9]. The original questionnaire is
available from: http://pos-pal.org/maix/pos-s-in-english.php.
MSAS-SF
The MSAS-SF is a validated self-reporting questionnaire
that includes 32 highly common physical and psycho-
logical symptoms [10]. It assesses the presence and
severity of 28 physical symptoms on a 5-point Likert
scale (from 0 = ‘not bothersome’ to 4 = ‘very bothersome’)
and the presence and frequency of four psychological
symptoms on a 4-point Likert scale (from 1 = ‘rarely
present’ to 4 = ‘almost constantly present’).
The MSAS-SF subscales include: 1) the Global Distress
Index (GDI), measuring four psychological symptoms
and six physical symptoms; 2) the Physical Symptom
Distress Score(PHYS) comprising 12 common physical
symptoms; and 3) the Psychological Symptom Distress
Score (PSYCH), including six common psychological
symptoms. The total number of symptoms (TNS) is the
sum of symptoms experienced. The scoring procedure
follows the instructions of Portenoy et al. for the short
Fig. 1 Flowchart of the translation of the POS-S Renal from English
to Spanish. Two forward translations were performed by two translators.
Two native English translators performed a backward translation. The
back-translated version was compared with the original version to
create a consensus document, which was pilot tested to provide a
final version
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form [25]. The MSAS-SF has been cross-culturally adapted
to Spanish speakers and has shown adequate psychometric
properties [26]. It has been widely used in patients with
ACKD [18–20].
Psychometric evaluation of the questionnaire
Reliability Reliability was considered as test-retest
reliability. To evaluate this, 73 patients completed the
Spanish POS-S Renal twice, separated by 7 days. Pearson’s
r correlation coefficient was used for assessment of the
test-retest reliability.
Internal consistency Internal consistency concerns
whether there is a satisfactory degree of interrelatedness
among the items. To evaluate this psychometric property,
Cronbach’s α coefficients were calculated using the
intraclass correlation coefficient type 2.1two-way mixed
effects model, where people effects are random and mea-
sures effects are fixed (ICC2.1) [27].
Internal structure Internal structure refers to the degree
to which the scores for a questionnaire are an adequate
reflection of the dimensionality of the construct to be
measured. Exploratory factor analysis (EFA) with
maximum likelihood extraction (MLE) and varimax ro-
tation was used to evaluate this psychometric property.
To confirm the factor model, we performed confirma-
tory factor analysis (CFA).
Concurrent criterion-related validity Concurrent cri-
terion-related validity refers to the degree to which the
scores for an instrument are associated with scores for
other instruments that are intended to evaluate similar
constructs. This psychometric property was measured
using the MSAS-SF as a reference, and Pearson’s r
correlation coefficient was used to examine correlations
between factor 1 of POS-S Renal and MSAS-SF total
score, between factor 2 of POS-S Renal and MSAS-SF
total score, and between the total score of POS-S Renal
and MSAS-SF.
Table 1 Socio-demographic and Clinical Characteristics of the Sample (N = 200)
Characteristics Tota (N = 200) Conservative management group (n = 139) Dialysis group (n = 61)
Age (mean, SD) 66.45 (±14.5) 69.65 (±12.8) 59.15 (±15.4)
Gender
Male 130 (65%) 95 (68%) 35 (57.4%)
Female 70 (35%) 44 (32%) 26 (42.6%)
Ethnicity
Caucasian 199 (99.5%) 138 (99.3%) 61 (100%)
Spanish descent 193 (96.5%) 132 (94.9%) 61 (100%)
British descent 3 (1.5%) 3(2.2%) 0 (0%)
German descent 3 (1.5%) 3(2.2%) 0 (0%)
Indian 1 (0.5%) 1(0.7%) 0 (0%)
Marital status
Married 134 (67%) 94 (68%) 40 (65.6%)
Not married 66 (33%) 45 (32%) 21 (34.4%)
Causes of CKD
Renal vascular disease 66 (33%) 56 (40.5%) 10 (16.4%)
Diabetic nephropathy 32 (16%) 22 (16%) 10 (16.4%)
Primary glomerular disease 17 (8.5%) 9 (6.5%) 8 (13.1%)
Polycystic kidneys 13 (6.5%) 8 (6%) 5 (8.2%)
Unknown aetiology 27 (13.5%) 19 (14%) 7 (11.5%)
Others 45 (22.5%) 24 (17%) 21 (34.4%)
Barthel index (mean, SD) 94.8 (±9.8) 94.93 (±9.5) 94.59 (10.3%)
Charlson comorbidity index
2–3 83 (41.5%) 56 (40.3%) 27 (44.3%)
4–5 85 (42.5%) 58 (41.7%) 27 (44.3%)
≤ 6 32 (16%) 25 (18%) 7 (11.4%)
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Statistical analysis
Descriptive statistical analysis was used to determine the
means and standard deviation of the sociodemographic
and clinical variables and the POS-S Renal. We tested
the differences in the responses from patients in dialysis
and patients in conservative management using one-way
analysis of variance (ANOVA).
Statistical analysis was conducted to assess the test-
retest reliability, internal consistency, internal structure
and concurrent criterion validity. The sample distribution
was determined by Kolmogorov–Smirnov (KS) test. The
Pearson’s r correlation coefficient used the criteria of: poor
(an r < 0.49), fair (0.50 ≤ r ≤ 0.74), and strong (an r > 0.75)
[28]. We assessed the measurement model of the POS-S
Renal using CFA. The model fit indices included chi-square
(χ2), root mean square error of approximation (RMSEA),
and the comparative fit index (CFI). For RMSEA, values of
0.08 or below indicate a close fit [29]. This analysis was
conducted using SPSS version 20 and LISREL 8.80 [30].
Results
Translation and cultural adaptation
The POS-S Renal was translated and back-translated
without language difficulties to provide the Spanish
modified version of the instrument (Additional file 1). The
mean ± SD time to complete the questionnaire at the first
administration was 7 ± 2.5 min. The Spanish modified
version of the POS-S Renal showed a low proportion of
missing responses (this did not exceed 2%). The charac-
teristics of the study sample are shown in Table 1.
Response from patients in dialysis and patients having
conservative management showed no significant differ-
ences (p = 0.130 to factor 1 and p = 0.455 to factor 2).
Pilot study
The translated and modified version of the POS-S Renal
proved to be comprehensible and easy to complete during
the pilot testing, and changes in format were not needed.
The questionnaire was readable and acceptable by the
target population (Additional file 2).
Validation study
Test-retest reliability
The test–retest reliability was satisfactory. Pearson’s
correlation coefficient was: r = 0.909 to factor 1, r = 0.695
to factor 2, r = 0.887 to total score and P < 0.001.
Internal consistency
The adapted questionnaire presented good internal
consistency to factor 1 (α = 0.78, item range from 0.74
to 0.83) and moderate internal consistency to factor 2
(α = 0.56, item range from 0.45 to 0.65).
Internal structure: factor analysis
The Kaiser-Meyer-Olkin values (0.773) and Bartlett’s
Test of Sphericity (P < 0.001) indicated that the correl-
ation matrix for the POS-S Renal was suitable for MLE.
The factor analysis revealed that 35.05% of the variance
could be explained with two factors with an eigenvalue
higher than 1 and 10% of variance explained, and
61.01% with six factors with an eigenvalue higher than 1.
The results are shown in Table 2. These six factors were
used for the rotated component matrix. The scree plot
indicated a two-factor solution (see Fig. 2). The item
loading
for the two-factor solution is shown in Table 3. The fit
indices of the two factor model indicated an excellent fit:
χ2 = 222.82, RMESA= 0.68 and CFI = 0.98 (Fig. 3) [31].
Concurrent criterion-related validity
The correlation between the POS-S Renal and the MSAS-
SF was confirmed. The POS-S Renal showed adequate
correlations with the MSAS-SF. The values of the correla-
tions were 0.809 (factor 1 – MSAS-SF total score), 0.518
(factor 2 – MSAS-SF total score) and 0.860 (POS-S Renal
total score – MSAS-SF total score). The results demon-
strated the value of the POS-S Renal as a multidimen-
sional measure.
Discussion
The translation and cross-cultural adaptation of the
POS-S Renal into Spanish using recognised international
guidelines was achieved satisfactorily. To our knowledge,
this study is the first cross-cultural adaptation and psycho-
metric analysis of the POS-S Renal. The study sample
included dialysis and conservatively managed patients.
Although the POS-S Renal is an instrument to measure
symptoms in conservatively managed ACKD patients,
in our experience it has been a useful clinical assessment
tool for the dialysis population. We tested responses from
patients in these two categories, and the results indicated
that there were no significant differences between the two
groups, although a trend towards a significant difference
Table 2 Total Variance Explained
Factor Eigenvalues
Total % of Variance Cumulative %
1 4.472 24.843 24.843
2 1.838 10.210 35.053
3 1.332 7.398 42.450
4 1.267 7.037 49.488
5 1.070 5.943 55.431
6 1.005 5.582 61.013
Extraction Method: Maximum Likelihood
a. When factors are correlated, sums of squared loadings cannot be added to
obtain a total variance
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in the responses between the groups for factor 1 was
found.
Excellent content validity of the Spanish modified ver-
sion was demonstrated, which indicates that all items of
this instrument are relevant for the measurement of the
symptomatology in ACKD [23, 24]. This instrument
showed satisfactory psychometric characteristics in terms
of reliability [27], structural validity [31], and concurrent
criterion-related validity [32]. The sample size was ad-
equate for all analyses [33].
We added ‘cramps’ to the original 17-item POS-S
Renal because of the frequency of cramps among patients
with ACKD [4, 5]. Although in our study the prevalence
of cramps was lower than has been found in other studies
on the Spanish population, this is a common symptom
that is often under-evaluated and is an important cause of
the early termination of dialysis sessions [34, 35].
The test–retest reliability was high (r = 0.887 to total
score), with values beyond those found in the modified
ESAS in dialysis patients (r = 0.7 to total score) [11].
Internal consistency analysis indicated a satisfactory
degree of interrelatedness among the items of the in-
strument [27]. Factor 1(α = 0.78) and factor 2 (α = 0.56)
showed the highest and lowest results, respectively,
with values below those found in the Arabic translation
and modification of the DSI (Cronbach’s α = 0.91
overall) [36].
The two-factor solution obtained in the EFA accounted
for a significant proportion of variance and showed sup-
port for the presence of construct validity, which provides
support for evidence of the instrument validity. The factor
analysis performed to evaluate the internal structure of
the POS-S Renal confirmed the two-factor model, in line
with other symptom assessment tools [25]. However, we
performed a CFA, and the fit indices of the CFA model
were satisfactory [29]. Nonetheless, two POS-S Renal
items, namely, restless legs and changes in skin, did not
Fig. 2 Scree plot of the exploratory two factor solution
Table 3 Factor Structure of Rotated Component Matrix
Item Component
1 2
Pain 0.555 −0.162
Shortness of breath 0.497 −0.318
Weakness or lack of energy 0.547 −0.379
Nausea 0.251 −0.779
Vomiting 0.196 −0.694
Poor appetite 0.398 −0.236
Constipation 0.305 −0.001
Mouth problems 0.558 −0.305
Drowsiness 0.433 −0.320
Poor mobility 0.672 −0.050
Itching 0.361 −0.317
Difficulty sleeping 0.506 −0.386
Restless legs 0.150 −0.223
Feeling anxious 0.537 −0.303
Feeling depressed 0.586 −0.218
Changes in skin 0.329 −0.345
Diarrhoea 0.187 −0.486
Muscle cramps 0.229 −0.358
Extraction Method: Maximum Likelihood. Rotation Method: Oblimin with
Kaiser Normalisation. Suppression at 0.35
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load on either of these two factors. Consequently, it ap-
pears that these symptoms function as individual items.
A possible explanation for this is that these two symp-
toms are best regarded as ‘causal indicators’ not ‘indica-
tor variables’, and this suggests inherent problems with
the application of the factor analysis [37]. Causal indica-
tors are variables external to the patient that could affect
symptoms, and indicator variables are unobservable
variables which can be inferred from scores on mul-
tiple self-report items. Thus, the inclusion of indicator
variables in factor analysis could lead to uninterpret-
able results [37, 38].
The concurrent criterion-related validity analysis with
the MSAS-SF was supported by a strong correlation with
factor 1 and total score, and a fair correlation with factor
2, which provides support for evidence that the scores of
the POS-S Renal are an adequate reflection of a previously
validated instrument that has been widely used in patients
with ACKD. These results are in line with those found by
the authors of the Arabic translation of the DSI and the
modified ESAS with the Kidney Dialysis Quality of Life-
Short Form (KDQOL-SF) [11, 36].
The extent and severity of the symptom burden in pa-
tients with ACKD demonstrates the importance of using
an appropriate clinical tool [4, 5, 13, 15]. Likewise, the
multidimensional nature of the symptoms should be
considered in these patients [39]. The POS-S Renal is a
validated instrument that provides information about a
large number of physical and psychological symptoms.
This also demonstrates the value of POS-S Renal as a
useful and clinically appropriate symptom assessment tool
to facilitate a multidimensional symptom evaluation in
ACKD.
A patient with many mild symptoms can have a score
identical to a patient with fewer, but more distressing
symptoms, and a high score on even a single symptom
could indicate a high level of patient distress for one
symptom even if the patient’s total score is low. Thus,
clinicians must look at the patient’s score on each of the
18 Spanish modified version of the POS-S Renal symptoms
on its own, even though a total score can be obtained.
This study provides access to a PRO instrument to
assess symptoms in CKD stage 4–5 for Spanish speak-
ing populations. This single-page 18-item PRO is a self-
administered questionnaire that is comprehensible and
easy to complete. Hence, this study shows that this in-
strument will be of value in the symptom assessment of
patients with ACKD in clinical practice and in research.
Although this study contributes by filling the knowledge
gap on the validation and usefulness of POS-S Renal, as
Fig. 3 Confirmatory factor analysis of the two factor model of the Spanish version of POS-S Renal
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well as, on symptoms assessment in ACKD, subsequent
studies should be carried out to develop more refined
measuring tools in this area [40].
The limitations to consider in this study include the
lack of longitudinal data concerning other psychometric
characteristics. Although our study shows a preliminary
analysis of the psychometric properties of a modified
POS-S Renal, sensitivity to change and minimally import-
ant differences were not evaluated. Further work using
longitudinal data to determine responsiveness is needed to
define the use of these measures in cohort studies and
clinical trials that evaluate interventions. Finally, given the
lower internal consistency for factor 2, a confirmatory
factor analysis in a wide sample should be carried out
to explore and interpret the behaviour of this factor.
Conclusions
The Spanish modified version of the POS-S Renal
demonstrated a two-factor structure and provided a
PRO specific to the Spanish population that is valid and
reliable. This clinical tool is simple to complete and
easily understood. This instrument is comprehensive
and can capture the multidimensional aspects of a
range of symptoms. Consequently, the POS-S Renal
can be recommended for clinical and research pur-
poses in Spanish speaking populations.
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